Thiophene

Thiophene is a privileged pharmacophore in medicinal chemistry with over 20 FDA-approved small-molecule drugs bearing the thiophene scaffold in . These compounds have been used across a range of therapeutic areas spanning anti-diabetic, anticancer, anti-inflammatory, anticonvulsant, and antioxidant activity. The sulfur atom confers an increased polarisability and a degree of lipophilicity relative to the oxygen-containing bioisosteres, while the aromatic character of the ring provides metabolic stability and supports productive π-stacking and hydrophobic contacts within binding sites. Thiophene is well established as a non-classical bioisostere for benzene, and its introduction into a lead series can modulate lipophilicity, improve membrane permeability, and block metabolic soft spots without significantly altering the geometry of pharmacophoric substituents. A notable structural consideration is that thiophene metabolism can generate reactive S-oxide and epoxide intermediates that are cytochrome P450-dependent, and this reactivity profile is managed through strategic halogen or alkyl substitution at vulnerable ring positions during lead optimisation.

Some of the approved molecules featuring the thiophene motif include: Rivaroxaban (Xarelto, Bayer), the first oral direct factor Xa inhibitor approved by the FDA in 2011 for the prevention and treatment of venous thromboembolism, incorporates a 5-chlorothiophene-2-carboxamide P1 group whose non-basic chlorine substituent makes a direct halogen interaction with Tyr228 at the base of the S1 pocket of factor Xa, a novel binding mode that enabled high potency to be combined with the oral bioavailability expected of a non-basic compound. Oliceridine (Olinvyk, Trevena), the first FDA-approved G-protein-biased µ-opioid receptor agonist, approved in August 2020 for the management of moderate to severe acute pain in adults in controlled clinical settings, incorporates an unfused 3-methoxythiophen-2-yl group as the key pharmacophoric element, where the methoxy-substituted thiophene ring contributes to the compound's distinctive receptor binding profile and selectivity for G-protein signalling over β-arrestin recruitment — a mechanistic distinction proposed to underlie its improved tolerability relative to conventional opioid analgesics and a design rationale that illustrates how thiophene substitution can be used to fine-tune functional selectivity at a GPCR target.

Our range of thiophenes features novel substitutions and the incorporation of synthetically tractable functional groups such as boronic acids and esters, amines, carboxylic acids, ketones, hydroxyls and halogens to enable expedient synthetic strategies.

Please examine a selection of thiophenes in our catalogue. The full range can be found using the substructure feature of our Search tools.